A 58-year-old man presents to the ophthalmology clinic for routine eye examination. He is asymptomatic and denies any visual complaints. On examination, intraocular pressure (IOP) is 24 mmHg in both eyes (normal <21 mmHg). Gonioscopy reveals an open angle with normal trabecular meshwork appearance. Optic disc examination shows a vertical cup-to-disc ratio of 0.7 with inferior neuroretinal rim thinning and a flame-shaped hemorrhage at the disc margin. Automated perimetry shows a superior arcuate scotoma. What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis: Established Primary Open-Angle Glaucoma (POAG) ### Key Findings Supporting POAG **Key Point:** This patient has all cardinal features of established POAG: elevated IOP, open angle on gonioscopy, optic nerve head damage (vertical CDR 0.7, inferior rim thinning, disc hemorrhage), and corresponding visual field defect (superior arcuate scotoma). ### Pathophysiology of POAG 1. Progressive trabecular meshwork dysfunction → increased outflow resistance 2. Chronic elevation of IOP → mechanical compression of axons at lamina cribrosa 3. Vascular insufficiency → ischemic optic nerve damage 4. Glial activation and apoptosis → irreversible axonal loss ### Management Algorithm for Established POAG ```mermaid flowchart TD A[Confirmed POAG with optic nerve damage + VF defect]:::outcome --> B{Target IOP achieved?}:::decision B -->|No| C[Initiate medical therapy]:::action C --> D[Start prostaglandin analogue monotherapy]:::action D --> E[Titrate to target IOP]:::action E --> F{IOP at target?}:::decision F -->|Yes| G[Continue monotherapy + monitor]:::action F -->|No| H[Add second agent or escalate]:::action B -->|Yes| I[Continue current regimen]:::action ``` ### Rationale for Prostaglandin Analogue Monotherapy | Feature | Prostaglandin Analogue | Rationale | |---------|------------------------|----------| | **Efficacy** | 25–35% IOP reduction | Highest among all monotherapies | | **First-line status** | Yes, in POAG | Preferred initial agent per AAO/ESCRS guidelines | | **Mechanism** | ↑ Uveoscleral outflow | Addresses primary pathology (trabecular dysfunction) | | **Dosing** | Once daily (evening) | Convenient; improves compliance | | **Side effects** | Iris pigmentation, lash growth | Cosmetic, not vision-threatening | **High-Yield:** Prostaglandin analogues (latanoprost, travoprost, bimatoprost, tafluprost) are the **gold standard first-line agents** for POAG because they provide the greatest IOP reduction with once-daily dosing and excellent tolerability. ### Why NOT the Other Options? **Observation without treatment:** This patient has **established optic nerve damage and visual field loss**—waiting risks further irreversible axonal loss. Treatment is mandatory. **Laser trabeculoplasty:** Selective laser trabeculoplasty (SLT) is an adjunct or alternative if medical therapy fails, is not tolerated, or compliance is poor. It is not first-line in treatment-naïve patients with accessible medical options. **OCT angle imaging:** Gonioscopy has already confirmed an **open angle**. OCT angle imaging is useful in angle-closure suspects or when gonioscopy is inconclusive—not indicated here. ### Clinical Pearl **Clinical Pearl:** The presence of a **disc hemorrhage** (Drance hemorrhage) is a sign of active glaucomatous damage and warrants urgent IOP lowering. It often precedes or accompanies visual field progression. ### Target IOP Concept **Key Point:** After initiating therapy, the target IOP is typically set 20–30% below the baseline IOP or to an absolute level <18 mmHg, depending on severity. In this patient with advanced optic nerve damage (CDR 0.7), a more aggressive target (e.g., <16 mmHg) may be appropriate.